Dive in

Nailing your monetization strategy has become more important than ever in today’s weakened macroeconomic climate, and it’s no longer as simple as charging per seat.

Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.

Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.

Since the advent of the internet, few technological advances have garnered as much attention and enthusiasm as quickly as generative AI.

Congratulations to Jeremy Zhang, Ansel Parikh, and the Finch team on raising their Series B.

At Manifest 2023, Menlo’s Steve Sloane moderated a panel with top supply chain experts to discuss current trends and shifts within the industry, as well as their predictions for the future.

At Menlo Ventures, we’ve invested in fintech for a long time and, despite the volatility of the last two years, believe there’s still a lot to be excited about.

Landing a new role in this market can feel daunting. But it’s not all doom and gloom for job seekers.

Economic downturns force us to get back to basics: The cost of new capital and low valuation multiples—even for top-performing public companies—force startups to make substantial progress per dollar to get a term sheet, much less an up round.

Cancer remains one of the leading causes of death in the U.S. and worldwide.

Supply chain is having a moment.

Software developers spend their days chasing the elusive “flow state:” headphones on, Slack notifications paused, dev environment humming along, context switching to a minimum, and delivering a significant amount of valuable code and/or solving a hard problem.

History may not repeat itself, but it often rhymes.

We held a fireside chat recently with Dali Rajic, COO at Zscaler, and invited senior sales leaders to discuss how to scale a SaaS business with world-class process and leadership.